Mass spectrometry‐-based chemical proteomics analysis of dabrafenib target profiles in melanoma cells identified a putative interaction with GCN2, a predicted property not shared by another BRAF inhibitor, vemurafenib (16). The gene discussed is BRAF; the disease is melanoma.